Showing results (91-100 of 119) with videos related to
Sort By:
Pageof 12
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 1998
Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593H S Koops, M Vaglini, S Suciu, et al.The American Journal of Pediatric Hematology/Oncology|January 1, 1989
Effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and L-asparaginase for standard risk childhood acute lymphocytic leukemia: results of a Dutch phase III study (ALL V). A report on behalf of the Dutch Childhood Leukemia Study Group (DCLSG)A van der Does-van den Berg, E R van Wering, S Suciu, et al.The British Journal of Surgery|September 11, 2012
Prognosis in patients with sentinel node-positive melanoma without immediate completion lymph node dissectionA P T van der Ploeg, A C J van Akkooi, P Rutkowski, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1996
High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia. Results of protocol ALL VI from the Dutch Childhood Leukemia Study GroupA J Veerman, K Hählen, W A Kamps, et al.Leukemia|March 1, 1997
A randomized phase II study on the effects of 5-Aza-2'-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC Leukemia Cooperative Group phase II study (06893)R Willemze, S Suciu, E Archimbaud, et al.British Journal of Cancer|October 25, 2000
High tPA-expression in primary melanoma of the limb correlates with good prognosisC M Ferrier, S Suciu, W L van Geloof, et al.Leukemia|January 17, 2003
The stem cell mobilizing capacity of patients with acute myeloid leukemia in complete remission correlates with relapse risk: results of the EORTC-GIMEMA AML-10 trialS Keating, S Suciu, T de Witte, et al.Blood|November 5, 1997
Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer and the Dutch Belgian Hemato-Oncology Cooperative GroupB Löwenberg, S Suciu, E Archimbaud, et al.Leukemia|August 30, 2002
Chemotherapy only compared to chemotherapy followed by transplantation in high risk myelodysplastic syndrome and secondary acute myeloid leukemia; two parallel studies adjusted for various prognostic factorsM Oosterveld, P Muus, S Suciu, et al.British Journal of Haematology|September 30, 1998
The influence of HLA-matched sibling donor availability on treatment outcome for patients with AML: an analysis of the AML 8A study of the EORTC Leukaemia Cooperative Group and GIMEMA. European Organization for Research and Treatment of Cancer. Gruppo Italiano Malattie Ematologiche Maligne dell'AdultoS Keating, T de Witte, S Suciu, et al.Pageof 12